Testing effectiveness (Phase 2)Study completedNCT01279473
What this trial is testing
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
Who this might be right for
Chronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia
Novartis Pharmaceuticals 42